Insider · CIK 0001182471

RIEFLIN WILLIAM JL

Reports to the SEC for 7 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001182471

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-22	LYCALycia Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2026-08-11	LYCALycia Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+24.8K sh	—	—	24,840
2026-06-10	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+9,250 sh	—	—	9,250
2025-05-15	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+130K sh	—	—	130,000
2024-06-14	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+130K sh	—	—	130,000
2024-05-23	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+36.5K sh	—	—	36,490
2024-04-05	NGM BIOPHARMACEUTICALS INCU Disposition from Tender	Director	UDisposition from Tender	−5,172 sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCU Disposition from Tender	Director	UDisposition from Tender	−2.77M sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−78.4K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−80K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−80K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−75K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−50K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−225K sh	—	—	0
2024-03-28	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+11.9K sh	$7.58	+$90K	11,871
2023-09-08	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+55K sh	—	—	55,000
2023-06-16	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+65K sh	—	—	65,000
2023-05-24	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.9K sh	—	—	12,940
2023-05-10	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+78.4K sh	—	—	78,407
2023-03-31	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+6,026 sh	$14.52	+$87.5K	6,026
2022-06-08	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+65K sh	—	—	65,000
2022-05-25	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+8,500 sh	—	—	8,500
2022-03-31	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+5,207 sh	$16.80	+$87.5K	5,207
2022-03-03	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2021-05-28	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2021-03-17	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2020-11-19	RAPTRAPT Therapeutics, Inc.P Purchase	Director	PPurchase	+10K sh	$16.22	+$162K	18,000
2020-06-18	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2020-02-04	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+75K sh	—	—	75,000
2019-11-04	RAPTRAPT Therapeutics, Inc.C Conversion	Director	CConversion	+43.4K sh	—	—	60,056
2019-11-04	RAPTRAPT Therapeutics, Inc.C Conversion	Director	CConversion	+16.7K sh	—	—	76,722
2019-11-04	RAPTRAPT Therapeutics, Inc.P Purchase	Director	PPurchase	+8,000 sh	$12.00	+$96K	8,000
2019-11-04	RAPTRAPT Therapeutics, Inc. · Series A Preferred StockC Conversion	Director	CConversion	−260K sh	—	—	0
2019-11-04	RAPTRAPT Therapeutics, Inc. · Series B Preferred StockC Conversion	Director	CConversion	−100K sh	—	—	0
2019-10-30	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+15.3K sh	—	—	15,334
2019-10-30	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+3,333 sh	—	—	3,333
2019-04-08	NGM BIOPHARMACEUTICALS INCC Conversion	Director	CConversion	+56.7K sh	—	—	2,769,168
2019-04-08	NGM BIOPHARMACEUTICALS INCSeries A Preferred StockC Conversion	Director	CConversion	−50K sh	—	—	0
2019-04-08	NGM BIOPHARMACEUTICALS INCSeries B Preferred StockC Conversion	Director	CConversion	−6,668 sh	—	—	0
2016-07-05	XENOPORT INCU Disposition from Tender	Director	UDisposition from Tender	−31.7K sh	$7.03	−$223K	0
2016-07-05	XENOPORT INCU Disposition from Tender	Director	UDisposition from Tender	−281K sh	$7.03	−$1.98M	0
2016-07-05	XENOPORT INCU Disposition from Tender	Director	UDisposition from Tender	−68 sh	$7.03	−$478.04	0
2016-07-05	XENOPORT INCStock OptionsD Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	$7.03	−$176K	0
2016-07-05	XENOPORT INCStock OptionsD Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	$7.03	−$105K	0
2016-07-05	XENOPORT INCStock OptionsD Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	$7.03	−$105K	0
2016-07-05	XENOPORT INCStock OptionsD Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	$7.03	−$105K	0
2016-07-05	XENOPORT INCStock OptionsD Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	$7.03	−$105K	0
2016-07-05	XENOPORT INCStock OptionsD Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	$7.03	−$105K	0
2016-07-05	XENOPORT INCRestricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−5,000 sh	$7.03	−$35.2K	0
2016-06-24	Anacor Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−89K sh	$99.25	−$8.83M	0

Recent filings

Accepted (ET)
Oct 264
RIEFLIN WILLIAM JL0001182471-26-000007
SEC(opens sec.gov)
Jun 124
RIEFLIN WILLIAM JL0001182471-26-000002
SEC(opens sec.gov)
May 194
RIEFLIN WILLIAM JL0001415889-25-013719
SEC(opens sec.gov)
Jun 174
RIEFLIN WILLIAM JL0001415889-24-017162
SEC(opens sec.gov)
May 234
RIEFLIN WILLIAM JL0001415889-24-014378
SEC(opens sec.gov)
Apr 84
RIEFLIN WILLIAM JL0000950170-24-042619
SEC(opens sec.gov)
Apr 14
RIEFLIN WILLIAM JL0001415889-24-009605
SEC(opens sec.gov)
Sep 84
RIEFLIN WILLIAM JL0001209191-23-048786
SEC(opens sec.gov)
Jun 204
RIEFLIN WILLIAM JL0001209191-23-038449
SEC(opens sec.gov)
May 254
RIEFLIN WILLIAM JL0001209191-23-032297
SEC(opens sec.gov)
May 124
RIEFLIN WILLIAM JL0001209191-23-029189
SEC(opens sec.gov)
Apr 104
RIEFLIN WILLIAM JL0001209191-23-023945
SEC(opens sec.gov)

Companies

Address

C/O LYCIA THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 200

SOUTH SAN FRANCISCO, CA, 94080